The detection of protein drugs in doping control samples is associated with numerous challenges as not only a sufficient analytical sensitivity but also unambiguous identification and differentiation from endogenous analogues have to be ensured. Moreover, the structural complexity of proteins in general and, especially, when post-translational modifications such as glycosylations are present, necessitates the use of sophisticated technologies as for instance immunoassays and liquid chromatography interfaced with high-resolution tandem mass spectrometry. Consequently, it is of utmost importance to continuously improve the existing sports drug testing assays and also search for novel/improved biomarkers indicative of protein doping.
Walpurgis et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: